

To Study High-sensitivity C-Reactive Protein absorption in Patients with Acute Coronary Syndrome at M.Y. Hospital, Indore

Dr. Ashish Kumar Jain¹, Dr. Parul Jain^{2*}

¹Assoc. Prof Dept. of Cardiology, Mahatma Gandhi Memorial Medical College, Indore Madhya Pradesh India

²Assoc. Prof Modern Dental College & Research Centre, Gandhi Nagar, Airport Road, Indore Madhya Pradesh India

*Corresponding author: Dr. Parul Jain

| Received: 10.01.2019 | Accepted: 20.01.2019 | Published: 30.01.2019

DOI: 10.36347/sjams.2019.v07i01.037

Abstract

Original Research Article

Background: To Study High-sensitivity C-Reactive Protein absorption in Patients with Acute Coronary Syndrome. **Result:** The mean serum hs-CRP in different risk subgroups was similar in patients with and without many of the study risk factors/profiles (gender; $p=0.719$, and hypertension; $p=0.561$), while it was significantly higher in those with hyperlipidaemia ($p=0.028$), With diabetes ($p=0.047$) with a family history of CAD/CV death ($p=0.033$), history of smoking ($p=0.029$). **Conclusion:** This study was conducted after an ACS, a fact that might have contributed to lower lipid levels and blood pressure than in stable clinical conditions before the ACS. In addition, at this time, high fasting glucose levels could be related to stress-induced. Our study showed that CRP levels were raised in patients with ACS at time of admission, and further increased with the passage of time during hospital stay.

Keywords: High-Sensitivity, C-Rection Protein & ACS.

Study Designed: Observational Study

Copyright © 2019: This is an open-access article distributed under the terms of the Creative Commons Attribution license which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use (NonCommercial, or CC-BY-NC) provided the original author and source are credited.

INTRODUCTION

Over the past decade, identification of novel risk factors and predictors for CVD has been an area of major interest in preventive cardiology. Serum high sensitivity C-reactive protein (hs-CRP), a biomarker of inflammation, has been shown to effectively predict the risk of adverse cardiovascular (CV) events consistently. Serum hs-CRP levels may aid in identifying patients at high risk for a first CV event who might otherwise be missed by screening for lipids and other conventional risk factors alone[1].

Coronary heart disease (CHD) incidence is increasing in the developing countries [2]. A number of predisposing factors affect the development of ischemic heart disease (IHD) and to date, more than 246 risk factors, including dyslipidemia and atherosclerosis (AS), have been identified. In patients with CHD, risk stratification is important, as information about probability of cardiovascular events in future can help target therapy [3]. Several plasma markers of inflammation have been evaluated as potential tools for the prediction of the coronary events. These include, among others, serum amyloid A, IL-6, fibrinogen, homocysteine, apolipoprotein-A, apolipoprotein B-100 and C-reactive protein [4].

MATERIALS & METHODS

The Study was conducted at MGM, Medical College, and Indore during the period February 2017 to February 2018, total 200 patients with the clinical diagnosis of acute coronary syndrome, who were fulfill the following criteria, included in the study.

Inclusion Criteria

- Patients with acute coronary syndrome irrespective of risk factors.
- Patient/party willing to give informed consent for active participation in the study.

Exclusion Criteria

- Patients on statins for more than one month,
- Patients with any systemic infection,
- Patients with malignancies,
- Patients with rheumatologic/autoimmune diseases,
- Patients with chronic inflammatory disorders,
- Patients with renal/hepatic compromise,
- Patients with recent trauma.
- Patients' refusal to give consent.
- Patients with psychiatric illness and those under legal custody.

It was a hospital based non-comparative

prospective cross-sectional study. Serum hs-CRP assessment was performed using the IMMULITE method containing one monoclonal and one polyclonal anti-CRP antibodies. This method provides a measurement range from 0.1 to 500 mg/L.

Patients were divided into three risk groups according to serum hs-CRP levels.

- < 1 mg/L - low risk,
- 1-3 mg/L - average risk
- >3 mg/L- high risk.

RESULTS

Table-1: Levels of serum hs-CRP and Type of Presentation

Serum hs-CRP level (mg/l)	UA	NSTEMI	STEMI
<1 mg/l	10	2	4
1-3 mg/l	24	10	24
>3 mg/l	30	20	76
Total	64	32	104
Mean serum hs-CRP levels	2.51±1.39	3.24±2.68	5.29±3.17

Table-2: Serum hs-CRP level in different risk factors subgroups*

Characteristic	Sr. hs-CRP
Male	4.23±3.29
Female	3.19±3.12
<i>P</i> value	0.719
With diabetes	5.47±4.30
Without diabetes	3.36±2.79
<i>P</i> value	0.047
With systemic hypertension	3.67±2.14
Without systemic hypertension	4.32±3.17
<i>P</i> value	0.561
With dyslipidemia	5.96±3.49
Without dyslipidemia	2.47±1.62
<i>P</i> value	0.028
With a family history of CAD/CV death	5.61±4.81
Without a family history of CAD/CV death	3.94±2.26
<i>P</i> value	0.033
With history of smoking	4.23±3.14
Without history of smoking	2.56±2.94
<i>P</i> value	0.029

*Data are presented as mean ± standard deviation; data were analyzed by *t* tests

Serum HS-CRP level in different subgroups

The mean serum hs-CRP in different risk subgroups was similar in patients with and without many of the study risk factors/profiles (gender; $p=0.719$, and hypertension; $p=0.561$), while it was significantly higher in those with hyperlipidaemia ($p=0.028$), with diabetes ($p=0.047$) with a family history of CAD/CV death ($p=0.033$), history of smoking ($p=0.029$).

DISCUSSION

In our study we showed, the mean value of the serum hs-CRP levels in Indian subjects were 4.18 ± 3.30 mg/L, which is higher to those reported in other ethnic groups, and is much higher than that reported in Japanese subjects[5] consistent with studies to suggest that the concentration of serum hs-CRP is high in Indians[6,7].

The study showed that the plasma CRP levels were significantly increased in patients of ACS at time of admission as compared to controls. These results are consistent with Tomado *et al.* [8] and Gavusoglu *et al.* [9] who demonstrated increased CRP levels in patients with ACS within 6 hours of admission. Our results showed a significant difference of mean CRP levels in patients of NSTEMI, STEMI as compared to UA patients and are in consistence with and Kazmierczak *et al.* [10] who identified increase in the CRP levels in patients of STEMI and NSTEMI versus UA, mainly due to myocardial necrosis and release of cytokines mediated CRP response. A limited increase in the CRP levels in patients with UA could be due to low grade myocardial necrosis by ischemia, which is, however, not confirmed in this study.

CONCLUSION

This study was conducted after an ACS, a fact that might have contributed to lower lipid levels and

blood pressure than in stable clinical conditions before the ACS. In addition, at this time, high fasting glucose levels could be related to stress-induced.

Our study showed that CRP levels were raised in patients with ACS at time of admission, and further increased with the passage of time during hospital stay.

REFERENCES

1. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. *Circulation*. 2001;104:365-72.
2. Boon NA, Fox KAA, Bloomfield P, Bradbury A. Cardiovascular disease. In: Haslett C, Chilvers ER, Boon NA, College NR, Hunter JAA. *Davidson's Principles and Practice of Medicine*. 19th ed. Edinburgh: Churchill Livingstone. 2002; 357-481.
3. Nie Y, Cheng M, Chen H, Tang Y, Wu Q, Zhang Y, Liu X. Dynamic alteration of blood lipid and hemodynamics parameters and vascular intima in the process of atherosclerosis. *Sheng wu yi xue gong cheng xue za zhi= Journal of biomedical engineering= Shengwu yixue gongchengxue zazhi*. 2005 Feb;22(1):10-4.
4. Mosca L. C-reactive protein- to screen or not to screen? *N Engl J Med*. 2002; 347(20):1615-7.
5. Taniguchi H, Momiyama Y, Ohmori R, Yonemura A, Yamashita T, Tamai S, Nakamura H, Ohsuzu F. Associations of plasma C-reactive protein levels with the presence and extent of coronary stenosis in patients with stable coronary artery disease. *Atherosclerosis*. 2005 Jan 1;178(1):173-7.
6. Chandalia M, Cabo-Chan AV Jr, Devaraj S, Jialal I, Grundy SM, Abate N. Elevated plasma highsensitivity C-reactive protein concentrations in Asian Indians living in the United States. *J Clin Endocrinol Metab*. 2003;88:3773-6.
7. Chambers JC, Eda S, Bassett P, Karim Y, Thompson SG, Gallimore JR, Pepys MB, Kooner JS. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. *Circulation*. 2001 Jul 10;104(2):145-50.
8. Tomoda H, Aoki N. Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. *Am Heart J*. 2000; 140: 324-8.
9. Cavusoglu Y, Gorenek B, Alpay S, Unalir A, Ata N, Timuralp B. Evaluation of C-reactive protein, fibrinogen and antithrombin-III as risk factors for coronary artery disease. *Isr Med Assoc J*. 2001 Jan 1;3(1):13-6.
10. Kazmierczak E, Sobieska M, Kazmierczak M, Mrozikiewicz A, Wiktorowicz K. Intense acute phase response in ischemic patients. *Int J Cardiol*. 1999;68:69-73.